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The National Alopecia Areata Registry was awarded as a
¢ve-year contract by NIAMS to promote research on the
genetic basis of alopecia areata. The registry is Web based
and can be accessed online at http://www.AlopeciaAreata
Registry.org. Samples of DNA, lymphoblast lines, and
sera, as well as epidemiology and quality-of-life data,
are being collected from well-characterized individuals,
multiplex families, and sib pairs for future research
studies and investigators. Keywords: hair/T-cell/HLA/autoim-
mune. JID Symposium Proceedings 8:219 ^221, 2003
A
lopecia Areata (AA) is an organ-speci¢c, T cell^
mediated autoimmune disease in which hair follicles
surrounded by lymphocytes have abnormal kerati-
nocyte di¡erentiation resulting in breakage of anti-
gen hairs and in baldness (Madani and Shapiro,
2000). Studies suggest that the process is generalized in the scalp,
although patches appear to be localized (Nutbrown et al, 1995). It
is estimated that in the United States over 2 million persons may
be a¥icted with the disease (Safavi et al, 1995).
Clinically, AA can present as patches of baldness on the scalp
or in other areas, such as the beard, which are reversible (Madani
and Shapiro, 2000). There is a spectrum of phenotypic severity
that culminates in total hair loss on the scalp (alopecia totalis,
AT) or total loss of all scalp and body hair (alopecia universalis,
AU).
AA has long been associated with other autoimmune diseases
(Cunli¡e et al, 1969; DuVivier and Munroe, 1975). Although most
consider AA to be a sporadic event, about 20%^50% of the af-
£icted give a positive family history of AA and autoimmunity
in other family members is not infrequently encountered (Duvic
et al, 2001). It is hypothesized that the release of in£ammatory
cytokines mediates this process and may be regulated by neuro-
peptide hormones.
The predisposition to autoimmune diseases is associated with
histocompatibility antigens (HLA) (Marrack et al, 2001). AA has
been associated with speci¢c class II histocompatibility antigens,
including HLA-DR-4 and HLA-DR-5 and associated DQB 03
alleles, in studies of unrelated patients versus controls (Duvic et al,
1991;Welsh et al, 1994; Kavak et al, 2000; Duvic et al, 2001). HLA
alleles may di¡erentiate between clinical phenotypes, in that the
patchy and persistent form of AA is sign¢¢cantly associated with
the HLA-DRB1104 allele of DR-5 whereas 80%^90% of all
patients with severe AT/AU were found to carry HLA-DQ03
alleles (Welsh et al, 1994; Colombe et al, 1995). Family studies using
transmission disequilibrium testing have supported the hypoth-
esis that AA is associated with the HLA-DR and DQ loci (Duvic
et al, 1995; De Andrade et al, 1999; Duvic et al, 2001).
Given the lack of Mendelian inheritance and the phenotypic
variation displayed by individuals with AA, the hypothesis that
AA is a complex genetic trait that depends on the cooperation
of a number of genes acting in concert is most attractive at this
time. An environmental trigger is likely to initiate the onset of
AA, as only a 55% concordancy rate was observed among sets
of identical twins who nonetheless all carried predisposing
DQB03 alleles (Jackow et al, 1998). Given the need for the collec-
tion of a large number of AA subjects for further linkage and
association studies, dermatology investigators from ¢ve sites ap-
plied for and were awarded an RFA to establish the National
Alopecia Areata Registry, to be funded by NIAMS.
BACKGROUND OF THE ALOPECIA AREATA REGISTRY
Following a peer review process, the Alopecia Areata Registry
was awarded to a collaborative group by NIAMS on September
23, 2000. Five experienced hair disease investigators, representing
the major geographic areas of the United States, competed for
this registry from among other groups representing other skin
diseases. The structure proposed for the AA registry, shown in
Fig 1, is a central site for specimen and data collection plus four
subsites where patients can be examined and enrolled across the
country.
The purpose of the national AA registry is to collect epide-
miology data, quality-of-life information, and sera and DNA
samples from well-characterized selected patients examined at
each site. The project involves the development of information
and questionnaires for the registry, the use of consent forms, and
a Web-based front end connected to a Microsoft database with
appropriate measures to ensure con¢dentiality of the patients in-
volved. Institutional Review Board approval was required from
each of the ¢ve involved institutions, and an OMB exemption
was required for collection of data.
The diagnostic criteria and severity for AA have been de-
scribed and published by a subcommittee of the National Alope-
cia Areata Foundation (Olsen et al, 1999). The degree of scalp hair
loss (S0-5), nail involvement (N0-2), and body hair loss (B0-2)
will be recorded for each patient accepted for long-form entry.
AA lesions should exhibit patches and broken hairs and be de-
void of tinea. The diagnosis of AA will require the exclusion
of other forms of alopecia by the use of appropriate cultures,
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biopsies on occasion, and lab tests such as RPR or ANA. Patients
who present at less than six months of age will be suspected as
having mutations in the hairless gene.
STRUCTURE OF THE ALOPECIA AREATA REGISTRY
Following the award, a steering committee, composed of the
principal investigators from each of the sites, was established to
oversee the operation of the registry. An external advisory board
of senior scientists was also selected and appointed. The steering
committee developed two questionnaires to be used to collect in-
formation from the registrants. At the central site, a Microsoft
SQL server database was constructed to contain patient question-
naires and collect all the data from them. A laboratory database
was constructed to decode and store the samples and link them
to the database information. An administrative database was set
up for the subsites to use for calling in patients in their regions
for examination.
Institutional Review Board review for the registry protocol,
questionnaires, and informed-consent forms was obtained from
each of the ¢ve sites.The ¢rst questionnaire is a self-administered,
short-intake form consisting of demographic information, AA
type, and personal and family history of autoimmune diseases.
Consent for the short form requires patients to read the introduc-
tion to the registry and choose to register online. The short ques-
tionnaire went on line in fall 2000. It is widely available to all
persons with AA, having been posted on the Web at http://
www.AlopeciaAreataRegistry.org. In addition, the short-form
questionnaire may be printed out from the Web site, ¢lled out
by hand, and mailed back to the registry for entry at the central
site.We encourage dermatologists to print out the short form and
give it to their AA patients or have them read the registry infor-
mation brochure.
The data from the short form goes directly into the central
SQL server database. An administrative database allows partition-
ing of the data where it can be seen regionally by each subsite
coordinator. This will allow scheduling of interested patients
and families who will come to the site to ¢ll out a longer form,
have an examination, and have samples of blood drawn and sent
to the central site for processing. Prior to ¢lling out a long form
and being examined, each patient will be required to sign a writ-
ten consent provided at the center.
Patients who belong to one of the categories listed in Fig 2 are
prioritized for the second tier of the registry. Multiplex families
(three or more a¡ected members) and a¡ected sib pairs or twins
plus their ¢rst-degree relatives will be of highest priority for ge-
netic studies. In addition, simplex families and single AA patients
with the more severe phenotype (AT/AU), patchy and persistent
AA, or transient AA will be registered for sample collection for
association studies.
The registry will enlist the help of local dermatologists in col-
lecting data and samples from multiplex family members who
may not be able to travel to a central site. Patients who are not
able to travel may be consented by phone and may have their
blood drawn locally after being examined by their dermatologist.
The data from the long form and from a quality-of-life question-
naire will be entered by hand into the database and linked to a
pedigree program. Each registrant and his or her family members
will be given unique patient identi¢ers. Digital photographs doc-
umenting the extent of the disease will be taken and stored. Each
site will collect information regarding biopsy results and labora-
tory tests from each patient who has long-form registration.
Blood samples will be collected from each long-form entrant
and processed for sera, white cells, and lymphoblast cell lines,
fromwhich genomic DNAwill be prepared. An unrelated spouse
or accompanying person will also be enlisted for samples to serve
as an una¡ected control.
UPDATE ON REGISTRATION
The registry has been open since fall 2001, and 686 individuals
have completed the short-form registration online or by hand.
Of the registrants, 396 listed their phenotype as AT or AU; 118,
as AA (82 with patchy persistent AA and 36 with transient AA).
There are 78 multiplex families, 64 simplex families, and 27 sib
pairs registered to date. Long-form data gathering from and
blood sampling of 70 individuals have been accomplished from
the central site and from the two other sites that have completed
IRB approvals.
Of note, the registryWeb site, AlopeciaAreataRegistry.org, has
had over 2000 hits, averaging 2000^3000 per month, or 60 per
day. Seventy percent of the visitors are from the United States,
8% are international, and the remainder are unknown. AOL and
Atomz are the most commonly used internet providers, at 8%
each.
PUBLICIZING THE ALOPECIA AREATA REGISTRY
For the registry to be a success, there must be widely distributed
information available, and we enlist the help of all dermatologists
in spreading the word to their patients and in reaching under-
served portions of the population. Advertisements have been
Figure1. Structure of the Alopecia Areata Registry.
• MULTIPLEX FAMILIES with 3 or more affected members plus
their first degree relatives
• AFFECTED SIB-PAIRS & parents 
• SINGLE PATIENTS with 
• Alopecia Totalis/Universalis for > 1 year 
• Alopecia Areata persistent for > 1 year 
• Transient, Mild Alopecia Areata for < 6 months 
Controls: spouse or friend
Total 2500 patients  
• DNA, sera, photos, selected biopsies
Figure 2. Selection of patients with AA for sample collection.
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placed in the major dermatology journals as of November 2002.
The details of the registry have been presented at the winter and
summer Academy meetings, at the SID meeting, at the Interna-
tional Hair Research Society meeting, and at local medical so-
ciety meetings. A brochure containing the contact information
for the registry and for each of the subsites has been developed
for physicians and their patients and can be found in Fig 3. All
dermatologists can help the registry by spreading the word to
their patients and to their colleagues in the community.
USING THE REGISTRY FOR RESEARCH
Investigators are encouraged to use the registry for conducting
AA research projects. They may apply by ¢lling out a form to
be provided online and reviewed by the steering committee.
Priority will be given to projects that are funded by NIAMS,
NIH, or NAAF grants. Con¢dentiality will be maintained for
all participants of the registry.
Information about the Registry The Alopecia Areata
Registry is a ¢ve-year, NIAMS-funded registry established to
collect epidemio-logy and quality-of-life data and samples for
genetic research leading to a better understanding of the patho-
genesis of Alopecia Areata and, hopefully, to improved therapy
for this common disease. Persons desiring more information
should contact one of the participating sites listed.
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Figure 3. Contact information for the Alopecia Areata Registry.
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